Moshe Szyf
Professor, Department of Pharmacology & Therapeutics
Szyf received his Ph. D from the Hebrew University and did his postdoctoral fellowship in Genetics at Harvard Medical School, joined the department in 1989 and currently holds a James 缅北强奸 Professorship and GlaxoSmithKline-CIHR Chair in Pharmacology. He is the founding co-director of the Sackler Institute for Epigenetics and Psychobiology at 缅北强奸 and is a Fellow of the Canadian Institute for Advanced Research Experience-based Brain and Biological Development program. 聽Szyf has been the founder of the first 鈥淧harma鈥 to develop epigenetic pharmacology 鈥淢ethylgene Inc.鈥 and the first journal in epigenetics 鈥淓pigenetics鈥.聽 Szyf lab has proposed two decades ago that DNA methylation is a prime therapeutic target in cancer and other diseases and has postulated and provided the first set of evidence that the 鈥渟ocial environment鈥 early in life can alter DNA methylation launching the emerging field of 鈥渟ocial epigenetics鈥.